Trials / Completed
CompletedNCT03467100
Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901
Phase 1, Double-blind, Placebo-controlled Study to Evaluate the Safety, Tolerability, and Pharmacokinetics of Single and Multiple Ascending Oral Doses of XEN901 in Healthy Subjects
- Status
- Completed
- Phase
- Phase 1
- Study type
- Interventional
- Enrollment
- 70 (actual)
- Sponsor
- Xenon Pharmaceuticals Inc. · Industry
- Sex
- All
- Age
- 18 Years – 55 Years
- Healthy volunteers
- Accepted
Summary
The XEN901 Phase 1 clinical trial is a randomized, double-blind, placebo-controlled study that will evaluate the safety, tolerability and pharmacokinetics (PK) of both single ascending doses (SAD) and multiple ascending doses (MAD) of XEN901 in healthy subjects. It is estimated there will be approximately 64 subjects in the planned SAD and MAD cohorts.
Conditions
Interventions
| Type | Name | Description |
|---|---|---|
| DRUG | XEN901 | Capsule filled with XEN901 |
| DRUG | Inert Ingredients Oral Product | Placebo capsule |
Timeline
- Start date
- 2018-02-19
- Primary completion
- 2018-12-19
- Completion
- 2018-12-19
- First posted
- 2018-03-15
- Last updated
- 2019-07-22
Locations
1 site across 1 country: United Kingdom
Source: ClinicalTrials.gov record NCT03467100. Inclusion in this directory is not an endorsement.